NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Humphrey L, Chan BKS, Detlefsen S, et al. Screening for Breast Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Aug. (Systematic Evidence Reviews, No. 15.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Screening for Breast Cancer

Screening for Breast Cancer [Internet].

Show details

Appendix 1. Bibliography of Mammography Screening Trails

References

    Health Insurance Plan of Greater New York

    1. Aron J L, Prorok P C. An analysis of the mortality effect in a breast cancer screening study. International Journal of Epidemiology. 1986;15(1):36–43. [PubMed: 3957541]
    2. Chu K C, Connor R J. Analysis of the temporal patterns of benefits in the Health Insurance Plan of Greater New York trial by stage and age [published erratum appears in Am J Epidemiol 1994 Aug 1;140(3):302] American Journal of Epidemiology. 1991;133:1039–1049. [PubMed: 2035504]
    3. Chu K C, Smart C R, Tarone R E. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. Journal of the National Cancer Institute. 1988;80:1125–1132. [PubMed: 3411625]
    4. Connor R J, Prorok P C, Weed D L. The case-control design and the assessment of the efficacy of cancer screening. Journal of Clinical Epidemiology. 1991;44(11):1215–1221. [PubMed: 1941016]
    5. Dodd G D. Introduction to “Evaluation of periodic breast cancer screening with mammography: methodology and early observations” by Shapiro, Strax and Venet [editorial] CA: A Cancer Journal for Clinicians. 1990;42(2):109.
    6. Final reports of National Cancer Institute ad hoc working groups on mammography screening for breast cancer and a summary report of their joint findings and recommendations DHEW Publication No. (NIH) 11 1400. Washington, DC: US Department of Health, Education and Welfare; 1977.
    7. Fink R, Shapiro S, Lewison J. The reluctant participant in a breast screening program. Public Health Reports. 1968;83(6):479–490. [PMC free article: PMC1891076] [PubMed: 4968124]
    8. Fink R, Shapiro S, Roester R. Impact of efforts to increase participation in repetitive screenings for early breast cancer detection. American Journal of Public Health. 1972;62(3):328–336. [PMC free article: PMC1530069] [PubMed: 5011163]
    9. Fink R, Shapiro S. Significance of increased efforts to gain participation in screening for breast cancer. American Journal of Preventive Medicine. 1990;6(1):34–41. [PubMed: 2187496]
    10. Friedman D R, Dubin N. Case-control evaluation of breast cancer screening efficacy. American Journal of Epidemiology. 1991;133(10):974–984. [PubMed: 2035508]
    11. Habbema J D, van Oortmarssen G, van Putten D J. An analysis of survival differences between clinically and screen-detected cancer patients. Statistics in Medicine. 1983;2(2):279–285. [PubMed: 6648143]
    12. Habbema J D, van Oortmarssen G J, van Putten D J, Lubbe J T, van der Maas P J. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. Journal of the National Cancer Institute. 1986;77(2):317–320. [PubMed: 3461193]
    13. Shapiro S, Goldberg JD, B. HG. Lead time in breast cancer detection and implications for periodicity of screening. American Journal of Epidemiology. 1974;100:357–366. [PubMed: 4417355]
    14. Shapiro S, Strax P, Venet L, Fink R. The search for risk factors in breast cancer. American Journal of Public Health & the Nations Health. 1968;58:820–835. [PMC free article: PMC1228493] [PubMed: 5689627]
    15. Shapiro S, Strax P, Venet L, Venet W. Changes in 5-year breast cancer mortality in a breast cancer screening program. Paper presented at: National Cancer Conference, 1972. [PubMed: 4764931]
    16. Shapiro S, Strax P, Venet L. Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. JAMA. 1966;195(9 Feb. 28):731–738. [PubMed: 5951878]
    17. Shapiro S, Strax P, Venet L. Evaluation of periodic breast cancer screening with mammography: methodology and early observations. CA: A Cancer Journal for Clinicians. 1990;40(2):111–125. [PubMed: 2106369]
    18. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reduced mortality from breast cancer. JAMA. 1971;215(11):1777–1785. [PubMed: 5107709]
    19. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Prospects for eliminating racial differences in breast cancer survival rates. American Journal of Public Health. 1982;72:1142–1145. [PMC free article: PMC1650189] [PubMed: 7114338]
    20. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. National Cancer Institute Monographs. 1985;67:65–74. [PubMed: 4047153]
    21. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. Journal of the National Cancer Institute. 1982;69:349–355. [PubMed: 6955542]
    22. Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomized trial: The health insurance plan (HIP) of greater New York study. In: Day NE, Miller AB, eds. Screening for breast cancer. Toronto: Hans Huber; 1988:3–15.
    23. Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: the Health Insurance Plan project and its sequelae, 1963-1986. Baltimore and London: The Johns Hopkins University Press; 1988.
    24. Shapiro S. A dissent from Dr. Schmidt's appraisal of evidence on breast cancer screening. Journal of Clinical Epidemiology. 1990;43(3):227–234. [PubMed: 2107281]
    25. Shapiro S. Determining the efficacy of breast cancer screening. Cancer. 1989;63(10):1873–1880. [PubMed: 2649218]
    26. Shapiro S. Evaluation of two contrasting types of screening programs. Preventive Medicine. 1973;2(2):266–277. [PubMed: 4579345]
    27. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Conference on Breast Cancer: A Report to the Profession. 1976:19–36.
    28. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer-(Philadelphia) 1977;39:2772–2782. [PubMed: 326378]
    29. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. Journal of the National Cancer Institute. Monographs. 1997;22:27–30. [PubMed: 9709271]
    30. Shapiro S. Screening: assessment of current studies. Cancer. 1994;74:231–238. [PubMed: 8004592]
    31. Shapiro S. The status of breast cancer screening: a quarter of a century of research. World-J-Surg. 1989;13:9–18. [PubMed: 2658359]
    32. Smart C R. Highlights of the evidence of benefit for women aged 40–49 years from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. Cancer. 1994;74(1 Suppl):296–300. [PubMed: 8004600]
    33. Strax P, Venet L, Shapiro S, Gross S, Venet W. Breast cancer found on repetitive examination in mass screening. Archives of Environmental Health. 1970;20(6):758–763. [PubMed: 4315318]
    34. Strax P, Venet L, Shapiro S, Gross S. Mammography and clinical examination in mass screening for cancer of the breast. Cancer. 1967;20(12):2184–2188. [PubMed: 6073895]
    35. Strax P, Venet L, Shapiro S. Mass screening in mammary cancer. Cancer. 1969;23(4):875–878. [PubMed: 5775978]
    36. Strax P, Venet L, Shapiro S. Value of mammography in reduction of mortality from breast cancer in mass screening. American Journal of Roentgenology, Radium Therapy & Nuclear Medicine. 1973;117(3):686–689. [PubMed: 4693025]
    37. Strax P. Advances in detection of early breast cancer. Cancer Detection and Prevention. 1983;6(45):409–414. [PubMed: 6652635]
    38. Strax P. Mass screening for control of breast cancer. Cancer. 1984;53(3 Suppl):665–670. [PubMed: 6692270]
    39. Strax P. Physical methods in breast cancer diagnosis. Israel Journal of Medical Sciences. 1981;17(910):847–853. [PubMed: 7309471]
    40. Strax P. The Health Insurance Plan of New York study: clinical aspects. Cancer. 1989;64(Suppl):2641–2644. [PubMed: 2819673]
    41. Thomas L B, Ackerman L V, McDivitt R W, Hanson T A S, Hankey B F, Prorok P C. Report of NCI ad hoc pathology working group to review the gross and microscopic findings of breast cancer cases in the HIP study. Journal of the National Cancer Institute. 1977;59(2):496–541.
    42. Vachieri C. Breast cancer screening: evidence of benefit for women 40–49. Journal of the National Cancer Institute. 1988;80:1090–1092.
    43. Walter S D, Stitt L W. Evaluating the survival of cancer cases detected by screening. Statistics in Medicine. 1987;6:885–900. [PubMed: 3438615]

    Canadian National Breast Screening Study 1 and 2

    1. Bailar J C 3rd, MacMahon B. Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. Can Med Assoc J. 1997;156(2):193–199. [PMC free article: PMC1226907] [PubMed: 9012720]
    2. Baines C J, Christen A, SImard A, Wall C, Dean D, Duncan L. The National Breast Screening Study: pre-recruitment sources of awareness in participants. Canadian Joural of Public Health. 1989;80(3):221–225. [PubMed: 2743247]
    3. Baines C J, Dayan R. A tangled web: factors likely to affect the efficacy of screening mammography [commentary] J Natl Cancer Inst. 1999;91(10):833–838. [PubMed: 10340902]
    4. Baines C J, McFarlane D V, Miller A B. Sensitivity and specificity of first screen mammography in 15 NBSS centres. Can Assoc Radiol J. 1988;39:273–276. [PubMed: 3060219]
    5. Baines C J, McFarlane D V, Miller A B. The role of the reference radiologist. Estimates of inter-observer agreement and potential delay in cancer detection in the national breast screening study. Invest Radiol. 1990;25(9):971–976. [PubMed: 2211054]
    6. Baines C J, McFarlane D V, Wall C. Audit procedures in the National Breast Screening Study: mammography interpretation. Can Assoc Radiol J. 1986;37(4):256–260. [PubMed: 2950109]
    7. Baines C J, Miller A B, Bassett A A. Physical examination. Its role as a single screening modality in the Canadian National Breast Screening Study. Cancer. 1989;63(9):1816–1822. [PubMed: 2702588]
    8. Baines C J, Miller A B, Kopans D B. et al. Canadian National Breast Screening Study: assessment of technical quality by external review. AJR Am J Roentgenol. 1990;155(4):743–747. discussion 748–749. [PubMed: 2119103]
    9. Baines C J, Miller A B, Wall C. et al. Sensitivity and specificity of first screen mammography in the Canadian National Breast Screening Study: a preliminary report from five centers. Radiology. 1986;160:295–298. [PubMed: 3523590]
    10. Baines CJ, Miller AB. Mammography versus clinical examination of the breasts. J Natl Cancer Inst Monogr. 1997(22):125–129. [PubMed: 9709288]
    11. Baines C J, To T, Wall C. Women's attitudes to screening after participation in the National Breast Breast Screening Study. A questionnaire survey. Cancer. 1990;65(7):1663–1669. [PubMed: 2311075]
    12. Baines C J, To T. Changes in breast self-examination behavior achieved by 89,835 participants in the Canadian National Breast Screening Study. Cancer. 1990;66(3):570–576. [PubMed: 2194648]
    13. Baines C J, Vidmar M, McKeown-Eyssen G, Tibshirani R. Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer. 1997;80:720–724. [PubMed: 9264355]
    14. Baines C J, Wall C, Risch H A, Kuin J K, Fan I J. Changes in breast self-examination behavior in a cohort of 8214 women in the Canadian National Breast Screening Study. Cancer. 1986;57(6):1209–1216. [PubMed: 3510711]
    15. Baines C J. A different view on what is known about breast screening and the Canadian National Breast Screening Study. Cancer. 1994;74(4):1207–1211. [PubMed: 8055439]
    16. Baines C J. Impediments to recruitment in the Canadian Breast Screening Study: response and resolution. Control Clin Trials. 1984;5(2):129–140. [PubMed: 6744885]
    17. Baines C J. NBSS: changes were made, suspicious changes were not. [letter; comment] Can Med Assoc J. 1997;157(3):248. 250. [PMC free article: PMC1227817] [PubMed: 9269191]
    18. Baines C J. Reflections on breast self-examination. Journal of the National Cancer Institute. 1997;89(5):339–340. [PubMed: 9060953]
    19. Baines C J. Screening for breast cancer: how useful are clinical breast examinations? Journal of the National Cancer Institute. 2000;92(12):958–959. [PubMed: 10861299]
    20. Baines CJ. Screening mammography in women 40 to 49 years of age: no. Important Adv Oncol. 1995:243–251. [PubMed: 7672810]
    21. Baines C J. The Canadian National Breast Screening Stucdy: current status. Developmental Oncology. 1987;51:25–27.
    22. Baines C J. The Canadian National Breast Screening Study. Why? What next? And so what?. [Review] [42 refs] Cancer. 1995;76(10 Suppl):2107–2112. [PubMed: 8635008]
    23. Baines C J. The Canadian National Breast Screening Study: a perspective on criticisms. Ann Intern Med. 1994;120:326–334. [PubMed: 8291826]
    24. Baines C J. The Canadian National Breast Screening Study: responses to controversy. Womens Health Issues. 1992;2(4):206–211. [PubMed: 1486284]
    25. Basinski A S. The Canadian National Breast Screening Study: opportunity to rethink. Can Med Assoc J. 1992;147(10):1431–1434. [PMC free article: PMC1336539] [PubMed: 1307231]
    26. Boyd N F, Byng J W, Jong R A. et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. Journal of the National Cancer Institute. 1995;87(9):670–675. [PubMed: 7752271]
    27. Boyd N F, Jensen H M, Cooke G, Han H L, Lockwood G A, Miller A B. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study. Eur J Cancer Prev. 2000;9(1):15–24. [PubMed: 10777006]
    28. Boyd N F, Jensen H M, Cooke G, Han H L. Relationship between mammographic and histological risk factors for breast cancer. Journal of the National Cancer Institute. 1992;87(9):1170–1179. [PubMed: 1635085]
    29. Boyd N F, Jong R A, Yaffe M J, Tritchler D, Lockwood G, Zylak C J. A critical appraisal of the Canadian National Breast Cancer Screening Study [editorial] Radiology. 1993;189:661–663. [PubMed: 8234686]
    30. Boyd N F, Lockwood G A, Martin L J. et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. Journal of the National Cancer Institute. 1999;91(16):1404–1408. [PubMed: 10451446]
    31. Boyd N F, Wolfson C, Moskowitz M. et al. Observer variation in the interpretation of xeromammograms. Journal of the National Cancer Institute. 1982;68:357–363. [PubMed: 7038244]
    32. Boyd N F. The review of randomization in the Canadian National Breast Screening Study. Is the debate over? [editorial; comment] Can Med Assoc J. 1997;156(2):207–209. [PMC free article: PMC1226910] [PubMed: 9012723]
    33. Bryant H. The review of randomization in the Canadian National Breast Screening Study. What does the verdict mean for clinicians? [editorial; comment] Can Med Assoc J. 1997;156(2):213–215. [PMC free article: PMC1226911] [PubMed: 9012724]
    34. Burhenne L J, Burhenne H J. The Canadian National Breast Screening Study: a Canadian critique. AJR Am J Roentgenol. 1993;161:761–763. [PubMed: 8372753]
    35. Busetti M C, Miller A B, To T, Rohan T E. Risk factors for breast cancer mortality among the National Breast Screening Study of Canada participants. Cancer Detect Prev. 1996;20(2):122–129. [PubMed: 8706037]
    36. Byng J W, Yaffe M J, Lockwood G A, Little L E, Tritchler D L, Boyd N F. Automated analysis of mammographic densities and breast carcinoma risk. Cancer. 1997;80(1):66–74. [PubMed: 9210710]
    37. Cohen M M, Kaufert P A, MacWilliam L, Tate R B. Using an alternative data source to examine randomization in the Canadian National Breast Screening Study. J Clin Epidemiol. 1996;49(9):1039–1044. [PubMed: 8780614]
    38. Deschamps M, Band P R, Coldman A J, Hislop T G, Longley D J. Clinical determinants of mammographic dysplasia patterns. Cancer Detect Prev. 1996;20(6):610–619. [PubMed: 8939347]
    39. Goel V, Cohen M M, Kaufert P, MacWilliam L. Assessing the extent of contamination in the Canadian National Breast Screening Study. Am J Prev Med. 1998;15(3):206–211. [PubMed: 9791638]
    40. Goldman B. When considering attacks against the National Breast Screening Study, consider the sources. Can Med Assoc J. 1993;148(3):427–428. [PMC free article: PMC1490483] [PubMed: 8439915]
    41. Gray C. US resistance to Canadian Mammogram study not only about data. Can Med Assoc J. 1993;148(4):622–623. [PMC free article: PMC1490507] [PubMed: 8431826]
    42. Haiart D C, Henderson J. A comparison of interpretation of screening mammograms by a radiographer, a doctor and a radiologist: results and implications. Br J Clin Pract. 1991;45(1):43–45. [PubMed: 1931542]
    43. Harvey B J, Miller A B, Baines C J, Corey P N. Effect of breast self-examination techniques on the risk of death from breast cancer. Can Med Assoc J. 1997;157(9):1205–1212. [PMC free article: PMC1228347] [PubMed: 9361639]
    44. Holowaty P H, Miller A B, Baines C J, Risch H. Canadian National Breast Screening Study: first screen results as predictors of future breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 1993;2:11–19. [PubMed: 8420606]
    45. Howe G, J. SG, B. SRMMA. Estimated benefits and risks of screening for breast cancer. Can-Med-Assoc-J. 1981;124:399–403. [PMC free article: PMC1705243] [PubMed: 7011526]
    46. Kopans D B, Feig S A. The Canadian National Breast Screening Study: a critical review. AJR Am J Roentgenol. 1993;161:755–760. [PubMed: 8372752]
    47. Kopans D B, Halpern E, Hulka C A. Mammography screening for breast cancer. Reply to the commentaries. Cancer. 1994;74(4):1212–1216. [PubMed: 8055440]
    48. Kopans D B, Halpern E, Hulka C A. Statistical power in breast cancer screening trials and mortality reduction among women 40–49 years of age with particular emphasis on the National Breast Screening Study of Canada. Cancer. 1994;74(4):1196–1203. [PubMed: 8055437]
    49. Kopans D B. Canadian National Breast Screening Study [letter; comment] Lancet. 1997;350(9080):810. [PubMed: 9298019]
    50. Kopans DB. Screening mammography in women 40 to 49 years of age: yes. Important Adv Oncol. 1995:231–241. [PubMed: 7672809]
    51. Kotwall C A, Mahoney L J. Screening mammography: interpretation of the data. Surg Oncol. 1994;3(5):305–307. [PubMed: 7889224]
    52. Mettlin C J, Smart C R. The Canadian National Breast Screening Study. An appraisal and implications for early detection policy. Cancer. 1993;72(4 Suppl):1461–1465. [PubMed: 8339239]
    53. Miller A B, Baines C J, Sickles E A. Canadian national breast screening study. AJR Am J Roentgenol. 1990;155:1133–1134. [PubMed: 2120947]
    54. Miller AB, Baines CJ, T. T, C. W. Screening mammography re-evaluated [letter]. Lancet. 2000;355(9205):747. [PubMed: 10703818]
    55. Miller A B, Baines C J, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years [published erratum appears in CMAJ 1993 Mar 1;148(5):718] Can Med Assoc J. 1992;147:1477–1488. [PMC free article: PMC1336544] [PubMed: 1423088]
    56. Miller A B, Baines C J, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years [published erratum appears in CMAJ 1993 Mar 1;148(5):718] Can Med Assoc J. 1992;147:1459–1476. [PMC free article: PMC1336543] [PubMed: 1423087]
    57. Miller AB, Baines CJ, To T. The Canadian national breast cancer screening study. In: Miller AB, Chamberlain J, Day NE, eds. Cancer Screening. Cambridge: Cambridge University Press; 1991:45–55.
    58. Miller A B, Baines C J, Turnbull C. The role of the nurse-examiner in the National Breast Screening Study. Can J Public Health. 1991;82(3):162–167. [PubMed: 1884309]
    59. Miller A B, Baines C J, Wall C. Re: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years [letter; reply] Journal of the National Cancer Institute. 2001;93(5):396–397. [PubMed: 11238702]
    60. Miller A B, Howe G R, Wall C. The National Study of Breast Cancer Screening Protocol for a Canadian Randomized Controlled trial of screening for breast cancer in women. Clinical & Investigative Medicine - Medecine Clinique et Experimentale. 1981;4:227–258. [PubMed: 6802546]
    61. Miller A B, To T, Baines C J, Wall C. The Canadian National Breast Screening Study: update on breast cancer mortality. J Natl Cancer Inst Monogr. 1997;22:37–41. [PubMed: 9709273]
    62. Miller A B, To T, Baines C J, Wall C. The Canadian National Breast Cancer Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst. 2000;92(18):1490–1499. [PubMed: 10995804]
    63. Miller A B, To T, Baines C J, Wall C. The Canadian National Breast Cancer Screening Study - I, breast cancer mortality after 11–16 years of follow-up in women age 40–49. Ann Intern Med. 2002;137:305–312. [PubMed: 12204013]
    64. Miller A B. Canadian national breast screening study [correction] Can Med Assoc J. 1993;148:718.
    65. Miller A B. Canadian National Breast Screening Study: public health implications. Can J Public Health. 1993;84:14–16. [PubMed: 8500048]
    66. Miller A B. Canadian National Breast Screening Study: response [letter] Can Med Assoc J. 1993;149(10):1374–1375. [PMC free article: PMC1485893] [PubMed: 8221414]
    67. Miller A B. Mammography in mass screening [letter] Eur J Cancer. 1980;16(5):737–739. [PubMed: 7389799]
    68. Miller A B. More on breast cancer screening. Cancer Forum. 1988;12:1–3.
    69. Miller A B. Re: “Author of Canadian breast cancer study retracts warning” [letter] Journal of the National Cancer Institute. 1992;84(17):1365–1371. [PubMed: 1495109]
    70. Miller A B. Re: May we agree to disagree, or how do we develop guidelines for breast cancer screening in women? [letter] Journal of the National Cancer Institute. 1994;86(22):1729–1731. [PubMed: 7966404]
    71. Miller A B. Routine mammography and the National Breast Screening Study. Can Med Assoc J. 1984;130(3):269–260. 273. [PMC free article: PMC1875348] [PubMed: 6692208]
    72. Miller AB. The Canadian National Breast Cancer Screening Study: update on breast cancer mortality. NIH Consensus Development Conference on Breast Cancer Screening for Women Ages 40–49; 1997:51–53.
    73. Miller AB. The Canadian national breast screening study. In: N.E. D, Miller AB, eds. Screening for breast cancer. Toronto: Hans Huber; 1988:51–58.
    74. Miller A B. The costs and benefits of breast cancer screening. Am J Prev Med. 1993;9(3):175–180. [PubMed: 8347369]
    75. Narod S A. On being the right size: a reappraisal of mammography trials in Canada and Sweden [letter] Lancet. 1997;349(9068):1846. [PubMed: 9269247]
    76. Narod S A. Re: Canadian national breast screening study-2: 13-year results of a randomized trial in women aged 50–59 years [letter] Journal of the National Cancer Institute. 2001;93(5):396–397. [PubMed: 11238702]
    77. Paci E, Alexander FE. Study design of randomized controlled clinical trials of breast cancer screening. J Natl Cancer Inst Monogr. 1997(22):21–25. [PubMed: 9709270]
    78. Simard A, Paquette L, Baillargeon J, Falardeau M. Perception of cancer detection and early treatment in a population participating in the National Breast Screening Study in Canada. Can J Public Health. 1989;80(3):226–227. [PubMed: 2743248]
    79. Tarone R. The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study. Cancer. 1995;75:997–1003. [PubMed: 7842421]

    Edinburgh Trial

    1. Alexander F, Roberts M M, Lutz W, Hepburn W. Randomisation by cluster and the problem of social class bias. Journal of Epidemiology and Community Health. 1989;43(1):29–36. [PMC free article: PMC1052787] [PubMed: 2592888]
    2. Alexander F E, Anderson T J, Brown H K. et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999;353(9168):1903–1908. [PubMed: 10371567]
    3. Alexander F E, Anderson T J, Brown H K. et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. British Journal of Cancer. 1994;70(3):542–548. [PMC free article: PMC2033341] [PubMed: 8080744]
    4. Alexander F E, Anderson T J, Donnan P, Prescott R J. Edinburgh trial of screening for breast cancer [letter] Lancet. 1990;335(8695):969.
    5. Alexander F E, Anderson T J, Hubbard A L. Screening status in relation to biological and chronological characteristics of breast cancers: a cross sectional survey. Journal of Medical Screening. 1997;4(3):152–157. [PubMed: 9368873]
    6. Alexander F E, Brown H K, Prescott R J. Improved classification of socio-economic status expalins differences in all-cause mortality in the randomised trial of breast cancer screening. Journal of Epidemiology and Biostatistics. 1998;3(2):219–224.
    7. Alexander F E, Roberts M M, Huggins A, Muir B B. Use of risk factors to allocate schedules for breast cancer screening. Journal of Epidemiology & Community Health. 1988;42(2):193–199. [PMC free article: PMC1052716] [PubMed: 3221171]
    8. Alexander F E. Estimation of sojourn time distributions and false negative rates in screening programmes which use two modalities. Stat-Med. 1989;8:743–755. [PubMed: 2664960]
    9. Alexander F E. The Edinburgh Randomized Trial of Breast Cancer Screening. Journal of the National Cancer Institute. Monographs. 1997;22:31–35. [PubMed: 9709272]
    10. Anderson T J, Lamb J, Alexander F, Lutz W, Chetty U, Forrest A P. Comparative pathology of prevalent and incident cancers detected by breast screening. Edinburgh Breast Screening Project. Lancet. 1986;1(8480):519–526. [PubMed: 2869259]
    11. Anderson T J, Lamb J, Donnan P. et al. Comparative pathology of breast cancer in a randomised trial of screening. British Journal of Cancer. 1991;64(1):108–113. [PMC free article: PMC1977297] [PubMed: 1854609]
    12. Anonymous. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet. 1999;353(9168):1909–1914. [PubMed: 10371568]
    13. Benjamin D J. The efficacy of surgical treatment of breast cancer. Medical Hypotheses. 1996;47(5):389–397. [PubMed: 8951803]
    14. Roberts M M, Alexander F E, Anderson T J. et al. The Edinburgh randomised trial of screening for breast cancer: Description of method. Br-J-Cancer. 1984;50:1–6. [PMC free article: PMC1976924] [PubMed: 6743506]
    15. Roberts M M, Alexander F E, Anderson T J. et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. 1990;335(8684):241–246. [PubMed: 1967717]

    The Malmo Trial

    1. Andersson I, Andren L, Hildell J, Linell F, Ljungqvist U, Pettersson H. Breast cancer screening with mammography: a population-based, randomized trial with mammography as the only screening mode. Radiology. 1979;132:273–276. [PubMed: 461778]
    2. Andersson I, Aspegren K, Janzon L. et al. Malmo mammographic screening trial. BMJ. 1989;298:49.
    3. Andersson I, Aspegren K, Janzon L. et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ. 1988;297:943–948. [PMC free article: PMC1834636] [PubMed: 3142562]
    4. Andersson I, Janzon L, Sigfusson B F. Mammographic breast cancer screening--a randomized trial in Malmo, Sweden. Maturitas. 1985;7:21–29. [PubMed: 2991708]
    5. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. Journal of the National Cancer Institute. Monographs. 1997;22:63–67. [PubMed: 9709278]
    6. Andersson I, Nystrom L. Mammography screening [letter] Journal of the National Cancer Institute. 1995;87(16):1263–1264. [PubMed: 7563176]
    7. Andersson I, Sigfusson B F. Screening for breast cancer in Malmo: a randomized trial. Recent Results in Cancer Research. 1987;105:62–66. [PubMed: 3296056]
    8. Andersson I. Breast cancer screening in Malmo. Recent Results in Cancer Research. 1984;90:114–116. [PubMed: 6366950]
    9. Andersson I. Detection bias in mammographic screening for breast carcinoma. Recent Results in Cancer Research. 1984;90:164–165. [PubMed: 6701373]
    10. Andersson I. Radiographic screening for breast carcinoma. I. Program and primary findings in 45–69 year old women. Acta-Radiol, Ser-Diagn. 1981;22:185–194. [PubMed: 6974454]
    11. Andersson I. Radiographic screening for breast carcinoma. II. Prognostic considerations on the basis of a short-term followup. Acta-Radiol, Ser-Diagn. 1981;22(3A):227–233. [PubMed: 7315500]
    12. Andersson I. Radiographic screening for breast carcinoma. III. Appearance of carcinoma and number of projections to be used. Acta-Radiol, Ser-Diagn. 1981;22:407–420. [PubMed: 7331853]
    13. Berglund G, Nilsson P, Eriksson K F. et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. Journal of Internal Medicine. 2000;247(1):19–29. [PubMed: 10672127]
    14. Gullberg B, Andersson I, Janzon L, Ranstam J. Screening mammography [letter] Lancet. 1991;337(8735):244. [PubMed: 1670878]
    15. Ikeda D M, Andersson I, Wattsgard C, Janzon L, Linell F. Interval carcinomas in the Malmo Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR. American Journal of Roentgenology. 1992;159(2):287–294. [PubMed: 1632342]
    16. Janzon L, Andersson I. Malmo mammographic screening trial. Cancer screening: Cambridge University Press; 1991:37–44.
    17. Ringberg A, Andersson I, Aspegren K, Linell F. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. European Journal of Surgical Oncology. 1991;17(5):466–476. [PubMed: 1657650]
    18. Tabar L, Duffy S. Malmo mammographic screening trial. BMJ. 1989;298:48–49. [PMC free article: PMC1835336] [PubMed: 2492859]

    The Stockholm Trial

    1. Frisell J, Eklund G, Hellstrom L, Glas U, Somell A. The Stockholm breast cancer screening trial - 5-year results and stage at discovery. Breast Cancer Research and Treatment. 1989;13:79–87. [PubMed: 2706329]
    2. Frisell J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist L E, Somell A. Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial. Breast Cancer Research & Treatment. 1991;18:49–56. [PubMed: 1854979]
    3. Frisell J, Eklund G, Hellstrom L, Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Research & Treatment. 1987;9:219–225. [PubMed: 3663958]
    4. Frisell J, Eklund G, Nilsson R, Hellstrom L, Somell A. Additional value of fine-needle aspiration biopsy in a mammographic screening trial. British Journal of Surgery. 1989;76:840–843. [PubMed: 2765842]
    5. Frisell J, Glas U, Hellstrom L, Somell A. Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons. Breast Cancer Research & Treatment. 1986;8:45–54. [PubMed: 3790749]
    6. Frisell J, Lidbrink E, Hellstrom L, Rutqvist L E. Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Research & Treatment. 1997;45:263–270. [PubMed: 9386870]
    7. Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40–49 years. Journal of the National Cancer Institute. Monographs. 1997;22:49–51. [PubMed: 9709275]
    8. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Research & Treatment. 1992;24:11–16. [PubMed: 1463867]
    9. Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ. 1996;312(7026):273–276. [PMC free article: PMC2349888] [PubMed: 8611781]
    10. Lidbrink E, Frisell J, Brandberg Y, Rosendahl I, Rutqvist L E. Nonattendance in the Stockholm mammography screening trial: relative mortality and reasons for nonattendance. Breast Cancer Research & Treatment. 1995;35:267–275. [PubMed: 7579497]
    11. von Rosen A, Frisell J, Glas U, Hellstrom L, Nilsson R, Skoog L. Non-palpable invasive breast carcinomas from the Stockholm screening project. Acta Oncologica. 1989;28(1):23–27. [PubMed: 2706131]
    12. von Rosen A, Frisell J, Nilsson R, Wiege M, Auer G. Histopathological and cytochemical characteristics of interval breast carcinomas from the Stockholm Mammography Screening Project. Acta Oncologica. 1992;31(4):399–402. [PubMed: 1321649]

    Swedish Two-County Study

    1. Andersson I, Fagerberg G, Lundgren B, Tabar L. Breast cancer screening in Sweden. The single modality approach. Radiologe. 1980;20:608–611. [PubMed: 7208897]
    2. Anonymous. Summary of the discussion on breast cancer screening. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge: Cambridge University Press; 1991:78–80.
    3. Arnesson L, Fagerberg G, Månson J. et al. Mammography screening: What is the diagnostic outcome in prevalent and repeated screening by an experienced team? Annales Chirurgiae et Gynaecologiae. 1989;78:33–33.
    4. Arnesson L G, Fagerberg G, Grontoft O, Lundstrom B. Surgical biopsy of non-palpable mammary lesions. Technique and results. Acta Chirurgica Scandinavica. 1986;152:97–101. [PubMed: 3513472]
    5. Arnesson L G, Smeds S, Fagerberg G, Grontoft O. Follow-up of two treatment modalities for ductal cancer in situ of the breast. British Journal of Surgery. 1989;76(7):672–675. [PubMed: 2548651]
    6. Arnesson L G, Smeds S, Fagerberg G. Recurrence-free survival in patients with small breast cancers. An analysis of cancers 10 mm or less detected clinically and by screening. Eur. J. Surg. Acta Chir. 1994;160:271–276. [PubMed: 8075195]
    7. Arnesson L G, Smeds S, Hatschek T, Nordenskjold B, Fagerberg G. Hormone receptors, ploidy and proliferation rate in breast cancers up to 10 mm. European Journal of Surgery. 1992;18(3):235–240. [PubMed: 1607034]
    8. Arnesson L G, Vitak B, Manson J C, Fagerberg G, Smeds S. Diagnostic outcome of repeated mammography screening. World Journal of Surgery. 1995;19(3):372–377. [PubMed: 7638991]
    9. Bergkvist L, Tabar L, Bergstrom R, Adami H O. Epidemiologic determinants of the mammographic parenchymal pattern. A population-based study within a mammographic screening program. American Journal of Epidemiology. 1987;126(6):1075–1081. [PubMed: 3687919]
    10. Chen H H, Tabar L, Fagerberg G, Duffy S W. Effect of breast cancer screening after age 65. Journal of Medical Screening. 1995;2:10–14. [PubMed: 7497137]
    11. Day N E, Williams D R, Khaw K T. Breast cancer screening programmes: the development of a monitoring and evaluation system. British Journal of Cancer. 1989;59(6):954–958. [PMC free article: PMC2246734] [PubMed: 2736233]
    12. Day NE. Surrogate measures in the design of breast screening trials. In: Miller AB, Chamberlain J, Day NE, eds. Cancer Screening. Cambridge: Cambridge University Press; 1991:391–403.
    13. de Koning H, Boer R, Warmerdam P, Beemsterboer P M, van der Maas P. Re: Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer screening trials [letter] Journal of the National Cancer Institute. 1996;88(1):52–55. [PubMed: 8847728]
    14. de Koning H J, Boer R, Warmerdam P G, Beemsterboer P M, van der Maas P J. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. Journal of the National Cancer Institute. 1995;87(16):1217–1223. [PubMed: 7563167]
    15. Duffy S, Tabar L, Krusemo UB, Day N. Randomization by cluster in the Swedish two-county trial: recent results from Kopparberg and implications for interpretation [abstract]. Paper presented at: Nordic Cancer Union, 1989; Stockholm.
    16. Duffy S W, Chen H H, Tabar L, Day N E. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statistics in Medicine. 1995;14:1531–1543. [PubMed: 7481190]
    17. Duffy S W, Chen H H, Tabar L, Fagerberg G, Paci E. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40–49. International Journal of Epidemiology. 1996;25:1139–1145. [PubMed: 9027517]
    18. Duffy S W, Day N E, Tabar L, Chen H H, Smith T C. Markov models of breast tumor progression: some age-specific results. Journal of the National Cancer Institute. Monographs. 1997;22:93–97. [PubMed: 9709283]
    19. Duffy S W, South M C, Day N E. Cluster randomization in large public health trials: the importance of antecedent data. Statistics in Medicine. 1992;11(3):307–316. [PubMed: 1609172]
    20. Duffy S W, Tabar L, Fagerberg G. et al. Breast screening, prognostic factors and survival - results from the Swedish two county study. British Journal of Cancer. 1991;64:1133–1138. [PMC free article: PMC1977849] [PubMed: 1764377]
    21. Ellman R. Breast cancer screening [editorial] Journal of the Royal Society of Medicine. 1987;80:665–666. [PMC free article: PMC1291082] [PubMed: 3694609]
    22. Fagerberg CJG, Tabar L. The results of periodic one-view mammography screening in a randomized, controlled trial in Sweden. In: Day NE, Miller AB, eds. Screening for breast cancer. Toronto: Hans Huber; 1988:33–38.
    23. Fagerberg G, Baldetorp L, Grontoft O, Lundstrom B, Manson J C, Nordenskjold B. Effects of repeated mammographic screening on breast cancer stage distribution. Results from a randomised study of 92 934 women in a Swedish county. Acta Radiologica - Oncology. 1985;24:465–473. [PubMed: 3006435]
    24. Fagerberg G. Experience from randomized controlled breast screening with mammography in Ostergotland county, Sweden: a preliminary report. Recent Results in Cancer Research. 1984;90:117. [PubMed: 6366951]
    25. Field S, Michell M J, Wallis M G, Wilson A R. What should be done about interval breast cancers? [editorial] BMJ. 1995;310(6974):224–226. [PMC free article: PMC2548611] [PubMed: 7866111]
    26. Forrest A P, Alexander F E. Re: Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer screening trials. Journal of the National Cancer Institute. 1996;88(1):52–55. [PubMed: 8847728]
    27. Hatschek T, Carstensen J, Fagerberg G, Stal O, Grontoft O, Nordenskjold B. Influence of S-phase fraction on metastic pattern and post-recurrence survival in a randomized mammography screening trial. Breast Cancer Research and Treatment. 1989;14(3):321–327. [PubMed: 2611405]
    28. Hatschek T, Fagerberg G, Stal O. et al. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer. 1989;64:1074–1081. [PubMed: 2758384]
    29. Hatschek T, Grontoft O, Carstensen J, Fagerberg G. Histopathological features and prognosis after fifteen years follow-up in a randomized population based trial of mammography screening [abstract]. Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1995;14:Abs. A137.
    30. Hatschek T, Grontoft O, Fagerberg G. et al. Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence. Breast Cancer Research & Treatment. 1990;15:149–160. [PubMed: 2196942]
    31. Holmberg L, Adami H O, Persson I, Lundstrom T, Tabar L. Demands on surgical inpatient services after mass mammographic screening. British Medical Journal. 1986;293:779–782. [PMC free article: PMC1341570] [PubMed: 3094655]
    32. Holmberg L, Baron J A, Byers T. et al. Alcohol intake and breast cancer risk: effect of exposure from 15 years of age. Cancer Epidemiology, Biomarkers and Prevention. 1995;4(8):843–847. [PubMed: 8634655]
    33. Holmberg L. Evaluation of breast cancer screening programs. Cancer. 1993;72(4 Suppl):1433–1436. [PubMed: 8339235]
    34. Holmberg L H, Tabar L, Adami H O, Bergstrom R. Survival in breast cancer diagnosed between mammographic screening examinations. Lancet. 1986;2:27–30. [PubMed: 2873324]
    35. Lindgren A. Autopsy and cause of death in randomized mammography studies. Quality Assurance in Health Care. 1993;5(4):303–307. [PubMed: 8018887]
    36. Lundstrom B, Fagerberg G. Clinical problems in relation to breast cancer screening with mammography. A preliminary report. Acta Chir Scand Supp. 1984;519:61–63. [PubMed: 6595925]
    37. Nixon R, Prevost T C, Duffy S W, Tabar L, Vitak B, Chen H H. Some random-effects models for the analysis of matched-cluster randomised trials: application to the Swedish two-county trial of breast-cancer screening. Journal of Epidemiology & Biostatistics. 2000;5(6):349–358. [PubMed: 11234739]
    38. Nystrom L, Rutqvist L E, Wall S. et al. Breast cancer screening with mammography: overview of Swedish randomised trials [published erratum appears in Lancet 1993 Nov 27;342(8883):1372] Lancet. 1993;341(8851):973–978. [PubMed: 8096941]
    39. Smart C R. Mammographic screening: efficacy and guidelines. Current Opinion in Radiology. 1992;4(5):108–117. [PubMed: 1388042]
    40. Tabar L, Akerlund E, Gad A. Five-year experience with sinle-view mammography randomized controlled screening in Sweden. Recent Results in Cancer Research. 1984;90:105–113. [PubMed: 6366948]
    41. Tabar L, Chen H H, Duffy S W, Krusemo U B. Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. Japanese Journal of Clinical Oncology. 1999;29:608–616. [PubMed: 10721943]
    42. Tabar L, Chen H H, Fagerberg G, Duffy S W, Smith T C. Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. Journal of the National Cancer Institute. Monographs. 1997;22:43–47. [PubMed: 9709274]
    43. Tabar L, Duffy S W, Burhenne L W. New Swedish breast cancer detection results for women aged 40–49. Cancer. 1993;72:1437–1448. [PubMed: 8339236]
    44. Tabar L, Duffy S W, Chen H H. Re: Quantitative interpretation of age-specific mortality reductions from the Swedish Breast Cancer-Screening Trials. Journal of the National Cancer Institute. 1996;88(1):52–55. [PubMed: 8847728]
    45. Tabar L, Duffy S W, Day N E. Screening with mammography [letter] International Journal of Technology Assessment in Health Care. 1990;6(3):498–500. [PubMed: 2228462]
    46. Tabar L, Duffy S W, Krusemo U B. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. European Journal of Cancer & Clinical Oncology. 1987;23:959–962. [PubMed: 3311769]
    47. Tabar L, Duffy S W, Vitak B, Chen H H, Prevost T C. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999;86(3):449–462. [PubMed: 10430253]
    48. Tabar L, Duffy S W. Criticisms of Swedish mammography trials were wrong [letter] BMJ. 1999;319(7221):1367. [PMC free article: PMC1117096] [PubMed: 10567156]
    49. Tabar L, Faberberg G, Day N E, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two- county breast cancer screening trial. British Journal of Cancer. 1987;55:547–551. [PMC free article: PMC2001715] [PubMed: 3606947]
    50. Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1. [PubMed: 2858707]
    51. Tabar L, Fagerberg CJG, Day NE. The results of periodic one-view mammographic screening in Sweden Part 2: Evaluation of results. In: Day NE, Miller AB, eds. Screening for breast cancer. Toronto: Hans Huber; 1988:39–44.
    52. Tabar L, Fagerberg CJG, South MC, Day NE, Duffy SW. The Swedish Two-county Trial of mammographic screening for breast cancer:recent results on mortality and tumour characteristics. In: Miller AB, Chamberlain J, Day NE, eds. Cambridge: Cambridge University Press; 1991:23–36.
    53. Tabar L, Fagerberg G, Chen H H, Duffy S W, Gad A. Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. Journal of Medical Screening. 1995;2:94–98. [PubMed: 7497163]
    54. Tabar L, Fagerberg G, Chen H H, Duffy S W. Tumour developoment, histology and grade of breast cancers: prognosis and progression. International Journal of Cancer. 1996;66(4):413–419. [PubMed: 8635853]
    55. Tabar L, Fagerberg G, Chen H H. et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer. 1995;75:2507–2517. [PubMed: 7736395]
    56. Tabar L, Fagerberg G, Day N E, Duffy S W. The Swedish Two-county Trial of mammographic screening for breast cancer:recent results on mortality and tumour characteristics. Pathol Biol Paris. 1992;39(9):846. [PubMed: 1538900]
    57. Tabar L, Fagerberg G, Duffy S W, Day N E, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiologic Clinics of North America. 1992;30:187–210. [PubMed: 1732926]
    58. Tabar L, Fagerberg G, Duffy S W, Day N E. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. Journal of Epidemiology & Community Health. 1989;43:107–114. [PMC free article: PMC1052811] [PubMed: 2512366]
    59. Tabar L, Fagerberg G, Duffy S W, Kitchin R M. Breast cancer treatment and natural history: new insights from results of screening. Lancet. 1992;339(8790):412–414. [PubMed: 1346670]
    60. Tabar L, Gad A, Akerlund E, Fors B, Fagerberg G, Baldetorp L. Screening for breast cancer in Sweden. A randomised controlled trial. In: Logan WW, Muntz EP, eds. Reduced dose mammography. New York: Masson; 1979:417–414.
    61. Tabar L, Gad A, Holmberg L, Ljungquist U. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagnostic Imaging in Clinical Medicine. 1985;54:158–164. [PubMed: 3896614]
    62. Tabar L, Gad A. Homberg L., Ljungquist U. Periodic screening with one-view mammography: the effect of mortality from breast cancer in a randomised, controlled trial [abstract] Br-J-Radiol. 1986;59:640.
    63. Tabar L, Gad A. Screening for breast cancer: the Swedish trial. Radiology. 1981;138:219–222. [PubMed: 7005939]
    64. Tabar L, Vitak B, Chen H H. et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiologic Clinics of North America. 2000;38(4):625–651. [PubMed: 10943268]
    65. Tabar L, Vitak B, Chen H H, Prevost T C, Duffy S W. Update of the Swedish Two-County Trial of breast cancer screening: histologic grade-specific and age-specific results. Swiss Surgery. 1999;5(5):199–204. [PubMed: 10546517]
    66. Tabar L, Vitak B, Chen H H T, Yen M F, Duffy S W, Smith R A. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001;91(9):1724–1731. [PubMed: 11335897]
    67. Tabar L. Control of breast cancer through screening mammography. Radiology. 1990:655–656. [PubMed: 2406778]
    68. Tabar L. Screening for breast cancer: an overview. Recent Results in Cancer Research. 1987;105:58–61. [PubMed: 3296055]
    69. Vitak B, Olsen K E, Manson J C, Arnesson L G, Stal O. Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers. European Radiology. 1999;9:460–469. [PubMed: 10087117]
    70. Vitak B. Invasive interval cancers in the Ostergotland Mammographic Screening Programme: radiological analysis. European Radiology. 1998;8:639–646. [PubMed: 9569340]

    Gothenburg Trial

    1. Bjurstam N, Bjorneld L, Duffy S W. et al. The Gothenburg Breast Cancer Screening Trial: preliminary results on breast cancer mortality for women aged 39–49 [letter] J Natl Cancer Inst Monogr. 1997;22:53–55. [PubMed: 9709276]
    2. Bjurstam N, Bjorneld L, Duffy S W. et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer. 1997;80(11):2091–2099. [PubMed: 9392331]
    3. Bjurstam N, Bjorneld L, Duffy S W, Prevost T C. Author reply. Cancer. 1998;83(1):188–190.
    4. Miller A B, Baines C J, To T. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization [letter; comment] Cancer. 1998;83(1):186–190. [PubMed: 9655310]

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...